The drivers of the success of Spanish Canoeing: an analysis of the efficiency of regional federations

Even though canoeing is not a particularly popular sport in Spain, it is one of the Olympic disciplines that has brought much success to the Spanish medal table. This high performance of Spanish canoeing could be attributed to the work of the clubs and regional federations (FFAA) which can optimise the scarce resources available to them, most of which come from public transfers. This study measures the efficiency of the Spanish autonomous canoeing federations (FFAAP) during the 2013-2016 Olympic cycle using the Data Envelopment Analysis (DEA) technique and the Malmquist index. A second analysis tries to identify the key factors that lead to the efficiency of the federations. The results show that, despite the significant differences between FFAAs, there is no single way to reach efficiency. In general, the availability of resources increases the chances of achieving results, while coaches and internal competition contribute to optimising the performance of available resources. © 2022 Federacion Espanola de Docentes de Educacion Fisica. All rights reserved

A Large Gene Network in Immature Erythroid Cells Is Controlled by the Myeloid and B Cell Transcriptional Regulator PU.1

PU.1 is a hematopoietic transcription factor that is required for the development of myeloid and B cells. PU.1 is also expressed in erythroid progenitors, where it blocks erythroid differentiation by binding to and inhibiting the main erythroid promoting factor, GATA-1. However, other mechanisms by which PU.1 affects the fate of erythroid progenitors have not been thoroughly explored. Here, we used ChIP-Seq analysis for PU.1 and gene expression profiling in erythroid cells to show that PU.1 regulates an extensive network of genes that constitute major pathways for controlling growth and survival of immature erythroid cells. By analyzing fetal liver erythroid progenitors from mice with low PU.1 expression, we also show that the earliest erythroid committed cells are dramatically reduced in vivo. Furthermore, we find that PU.1 also regulates many of the same genes and pathways in other blood cells, leading us to propose that PU.1 is a multifaceted factor with overlapping, as well as distinct, functions in several hematopoietic lineages

Evaluation of effluent organic matter fouling in ultrafiltration treatment using advanced organic characterisation techniques

Membrane fouling remains an operational challenge in the ultrafiltration (UF) membrane treatment of wastewater effluent and research is on-going to improve understanding of the organic character of foulants. Two advanced organic characterisation techniques that have potential to lend insight into membrane fouling are size exclusion chromatography with organic carbon, UV254 and nitrogen detection (LC-OCD) and fluorescence excitation-emission matrix (EEM) spectroscopy. In this study, UF treatment was undertaken for five tertiary wastewater effluents. The total hydraulic resistance was determined as well as that contributed by foulant layers fractionated by rinsing, backwashing and chemically desorbing. Organic characterisation for UF feed samples, permeates and each foulant layer was then performed using LC-OCD and FEEM spectroscopy with the aim of improving understanding of the character of foulants present in effluent organic matter (EfOM) and to determine the potential for the use of FEEM spectroscopy as a foulant indicator in such systems. It was determined that the biopolymer fraction was most significantly reduced on UF treatment, as anticipated due to its high molecular size. This was supported by the observation that the majority of the foulant layer comprised predominantly protein-enriched biopolymers (38-60% of total foulant layer DOC) that could be removed by rinsing. The resistance attributed to rinsing was directly related to the combined DOC concentration associated with proteins and low molecular weight neutral compounds as defined by LC-OCD analysis. Furthermore, tyrosine-like fluorescence intensity (λex/em=250/304nm) of both the rinsing solutions and UF feed samples showed good correlation with associated hydraulic resistance for EfOM originating from domestic wastewater, suggesting that fluorescence has potential to be used as a foulant indicator for these systems. © 2011 Elsevier B.V

Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors

Secondary hemolytic uremic syndrome (HUS) is a heterogeneous group of thrombotic microangiopathies associated with various underlying conditions. Whether it belongs to the spectrum of complement-mediated HUS remains controversial. We analysed the presentation, outcome, and frequency of complement gene rare variants in a cohort of 110 patients with secondary HUS attributed to drugs (29%), autoimmune diseases (24%), infections (17%), malignancies (10%), glomerulopathies (9%), extra-renal organ transplantation (8%), and pancreatitis (3%). The frequency of complement gene rare variants was similar in patients with secondary HUS (5%) and in healthy individuals (6% and 8% in French and European controls, respectively). At diagnosis, 40% of patients required dialysis and 18% had neurological manifestations. Fifty percent of patients received plasmatherapy and 35% were treated with eculizumab. Haematological and complete renal remission was achieved in 80% and 24% of patients, respectively. Thirty-nine percent of patients progressed to chronic kidney disease (stages 3-4) and an additional 37% reached end-stage renal disease. Eleven percent of patients died, most often from complications of the underlying cause of HUS. Only one patient experienced an HUS relapse. Patients treated with eculizumab presented with more severe HUS and were more likely to require dialysis at the time of diagnosis as compared to patients not treated with eculizumab. Rates of hematological remission, chronic kidney disease (stages 3-4), and end-stage renal disease were similar in the two groups. Secondary HUS is an acute nonrelapsing form of HUS, not related to complement dysregulation. The efficacy of eculizumab in this setting is not yet established